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Over the last decades, increasing interest has been attracted towards the nanotechnology which provide a set of promising re-
search tools and theranostic approaches. Tremendous research efforts in nanofabrication technology have led to the production 
or drugs against the metabolism or excretion. Furthermore, controlled delivery and targeted therapy may result in the improved 
-
materials capable of interaction with the nervous systems, and nanopharmaceuticals with minimal toxicity and improved bio-
has been highlighted. Biomed Rev 2018; 29: 17-26
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INTRODUCTION  
Enormous research efforts in nanotechnology and application 
-
tions have provided attractive research tools and theranostic 
approaches against a variety of disorders. High-resolution 
imaging may provide deeper understanding about the patho-
mechanisms of disorders leading to the selection of more ap-
propriate treatment strategies and obtaining better treatment 
outcomes. Real time detection of a variety of biomarkers and 
molecular signals or using the nanoscale-targeted magnetic 
resonance imaging (MRI) contrast agents demonstrate the 
immense potential of nanomaterials in the early diagnostics 
and prognostics (1, 2). Development of the biocompatible 
nanomaterials for protection of therapeutics against the me-
tabolism or excretion and overcoming the chemo-resistance 
R e v i e w
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might result in the improved treatment outcome. In this con-
text, designing the nanopharmaceuticals with improved half-
lives and bioavailability and targeted drug delivery systems 
using a variety of nanoparticles including the polymer- or 
lipid-based ones has attracted a growing interest. The ability 
of nanocarriers for improving the pharmacokinetics and in 
vivo stability of oligonucleotides, peptides, and proteins has 
conventional treatment strategies against the neurological 
diseases has resulted in designing the new treatment options 
such as the development of nanodevices capable of interaction 
with the nervous systems or multifunctional nanoparticles for 
delivery of therapeutics across the blood-brain barrier (BBB) 
for improving their bioavailability and reducing adverse effects 
(8). Nanotechnology along with tissue engineering are promis-
ing approaches for designing the controlled release systems 
containing the bioactive proteins or a variety of drugs which 
may re-establish the functional neuronal networks or neuronal 
connectivity (9-11). Carbon nanotubes (CNTs) with superior 
mechanical properties, improved biocompatibility, and high 
thermo-electrical conductivities, have shown enormous 
for biosensing, non-invasive and high-resolution imaging, 
CNTs may be applied as the carriers of therapeutics against a 
variety of disorders (12-18). Early detection of neoplastic or 
precancerous lesions has remained challenging that may be 
imaging technologies for early detection. Development of 
nanotech-based imaging technologies enables to provide bet-
molecular expressions of neoplasms, and detect the early-stage 
tumors (19). In recent years, increasing research efforts have 
been attracted towards the development of novel nanobiosen-
sors and nanotherapeutics for cancer theranostics (20-22). 
Nanocantilever arrays and nanowires may be applied for 
early detection of malignant lesions that may be of paramount 
importance in cancer therapy (23). Using nanocantilever, 
nanowire, and nanotube arrays facilitates the transition from 
single to multiple biomarker detection and selection of more 
appropriate strategies for cancer therapy (24). Nanoparticles 
may also be applied for biomarker detection ex vivo. For 
nanoparticles may be used for recognition of the molecular 
signatures and ultrasensitive detection of DNA, respectively 
(26). In prostate cancer, lymph-node metastases may not be 
detectable by traditional approaches, however, application of 
the lymphotropic paramagnetic nanoparticles may be helpful 
in this regard (27). Bimodal nanoparticles as the carriers of 
brain tumor imaging and intra-operative visualization of the 
lesions (28). In mice, gadolinium-loaded polymeric dendrim-
ers have been successfully applied for imaging the lymphatic 
of breast cancer (29). Nanoparticle probes which are targeted 
with recognition agents enable to obtain valuable information 
relating the distribution or abundance of cancer markers (30). 
Moreover, angiogenesis has been successfully imaged in the 
animals receiving targeted nanoparticle formulations (31). 
development of the next generation of therapeutics. 
NANOVECTORS
These nanostructures are usually applied for non-invasive 
visualization of the molecular markers or targeted delivery 
of therapeutics. Nanovectors protect the active agents against 
the enzymatic degradation, reduce the clearance time of 
peptide drugs, and overcome the biological barriers. Multi-
functionality and delivery of large amounts of imaging agents 
advantages of nanovectors. Using the biological targeting 
moieties enables to achieve a wide variety of new therapeutics. 
Several polymer-based nanovectors have been represented 
for application in the clinical settings (32, 33). For systemic 
administration of the nanovectors, silica and silicon may be 
applied (34, 35). Furthermore, metal-based nanovectors may 
be applied for localized thermal ablation that might be of sig-
of the active agent-loaded nanovectors may be achieved via 
conjugation with recognition moieties leading to the enhanced 
-
tors over traditional antibody-guided treatment strategies 
include the capability of carrying various targeting agents, 
delivery of greater therapeutic payloads, co-localized delivery 
of multiple active agents, and bypassing the biological bar-
riers (37). Indeed, barrier-avoiding nanovectors may provide 
nanovectors provides the optical-imaging signals that might be 
promising in targeted cancer therapies (38). Tumor-targeting 
mechanism or enhanced permeation and retention (EPR) is a 
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key issue which should be taken into account in development 
of the novel formulations of nanovectors (39). In this sense, 
application of the appropriate mathematical formulations 
may be useful for designing the nanovectors with optimized 
EPR (40). Co-administration of a bradykinin antagonist has 
been shown to increase the endothelial vascular permeability 
that may result in the enhanced EPR targeting of nanovectors 
(41). As follows, the widely-applied nanoparticle systems for 
biomedical applications including the polymeric and lipid 
nanoparticles have been highlighted. 
POLYMERIC NANOPARTICLES
Over the last decade, a variety of polymers have been devel-
oped for preparation of nanoparticles as the solid nanovectors 
which are usually prepared using the single materials. Polymer-
ic nanoparticles with high loading capacity appear to be more 
stable, easy-to-prepare, and safer than other nanocarriers. Non-
immunogenicity and rapid elimination from the body make the 
selected polymers as suitable candidates for development of 
nanoparticles with tunable surface properties and capable of 
encapsulating a variety of therapeutics. Selecting the proper 
polymeric carriers facilitates the controlled release of loaded 
scalability, biodegradability, and biocompatibility, appropriate 
linker design is of key importance for obtaining the optimal 
treatment outcome (44). Polymeric nanoparticles containing 
atherosclerotic plaques. This type of nanoparticles have been 
-
matory agents (45). Polymers may also be applied for delivery 
of water-soluble proteins and bio-imaging. Near-infrared dye 
loaded polymeric nanoparticles have been applied for cancer 
imaging and treatment (46). Using polyethyleneimine for 
preparation of biocompatible and cell-permeable polymeric 
be useful for visualizing caspase-dependent apoptosis (47).
-
noparticles may be applied for delivery of proteins, nucleic 
acids, or small molecule drugs to the central nervous system 
(CNS). For drug delivery into the CNS, various synthetic or 
natural polymers including the polyesters, poly(methylidene 
malonates), poly(alkylcyanoacrylates), or polysaccharides may 
be applied for preparation of the nanoparticles that may result 
in promising therapeutic effects against the neurodegenera-
tive disorders or malignancies (48-50). In recurrent gliomas, 
chemotherapeutic-loaded polymer nanoparticles capable of 
controlled drug delivery have improved the survival of patients 
(51). For treatment of the intracranial tumors, convection-
enhanced delivery (CED) of drug-loaded polymer nanopar-
ticles has been suggested as a useful approach which may 
transport the nanoparticles over the clinically relevant volumes 
of distribution (52, 53). Poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles loaded with camptothecin have been delivered 
via CED, an effective approach against the intracranial tumor 
model (54). Because of the attractiveness of CED, this strategy 
has been applied in the randomized clinical trials for delivery 
systemic toxicity (55). Meanwhile, intracranial CED may be 
impractical for a number of patients due to its invasivity. In 
this respect, controlling the size, surface coatings, and charge 
of polymer nanoparticles should be taken into consideration 
for more effective drug delivery (56). Microspheres have been 
towards the brain. Polymeric microspheres fabricated from a 
wide variety of materials such as chitosan, poly(methylidene 
malonate), poly(epsilon-caprolactone), or PLGA, may be ap-
plied for local delivery of various therapeutic agents against 
the malignant gliomas (57, 58). Noteworthy, delivery of the 
polymeric nanoparticles into the CNS largely depends on the 
adsorptive- or receptor-mediated transcytosis using targeting 
ligands or cell-penetrating peptides. Poly(butylcyanoacrylate) 
based nanocarriers for drug delivery into the CNS (59). Poly-
sorbate 80, a commonly used surfactant, increases the CNS 
penetration of PBCA nanoparticles that may be due to the 
with endothelial receptors of BBB, or reducing the clearance 
of nanoparticles (60, 61). Coating of PLGA nanoparticles 
of drug-loaded nanoparticles across the BBB (62). Follow-
ing the systemic administration, PLGA-, poly(glycolic acid) 
(PGA)-, or poly(lactic acid) (PLA)-based nanoparticles may 
penetrate the BBB in a size-dependent fashion (63). In order 
peptide has been attached to the surface of drug-loaded PLA 
nanoparticles leading to the enhanced transport of nanoparti-
cles into the CNS (64). Chitosan is a naturally occurring bio-
degradable and biocompatible polysaccharide which may be 
of therapeutics across the BBB (65). Following the systemic 
administration, chitosan nanoparticles capable of delivery 
of dopamine, caspase inhibitors, or peptides, have provided 
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promising neuroprotective effects (66). Moreover, cationic 
polymers may be applied for development of nanoparticles for 
nanoparticles with rabies virus glycoprotein-derived peptides 
enables the transvascular delivery of small interfering RNA 
to the CNS (67).
LIPID NANOPARTICLES
Lipid-based colloidal drug delivery systems including the 
nanostructured lipid carriers (NLCs) and solid lipid nano-
particles (SLNs) have been designed as the alternatives of 
polymeric nanoparticles, liposomes, or emulsions. This type 
of nanoparticles capable of targeted drug delivery and protect-
ing the loaded therapeutics against the enzymatic degradation, 
(68). Because of the limitations of SLNs including the drug 
expulsion during the storage and limited drug loading capacity 
(69), NLCs (the mixture of liquid and solid lipids) with long-
term stability, suitable biocompatibility, high drug loading 
the reduced drug dosage and side effects, are usually preferred 
for encapsulating of poorly water-soluble therapeutics (70). 
Because of the biocompatibility of excipients and aqueous 
nature, NLCs are suitable for intravenous drug delivery (71).
Application of NLCs in cancer chemotherapy may result 
in the improved therapeutic index of loaded anti-cancer 
agents (72). Besides application for tumor targeting, NLCs as 
sustained-release drug carrier systems have been represented 
as promising nanoformulations against the ischemic neural 
injuries, fungal infections, and leukemia (73-78). 
      Atorvastatin, a widely applied lipid-regulating drug, 
-
In this respect, designing the drug delivery systems capable 
of improving drug solubility and bypassing the hepatic me-
tabolism might be of therapeutic importance. Development of 
atorvastatin-loaded NLCs by high-speed homogenization and 
the drug indicating the appropriateness of NLC formulations 
(79). As compared to the commercially available tacrolimus 
ointment, tacrolimus-loaded NLCs have shown enhanced skin 
penetration (80). Regarding the inhalation drug delivery, NLCs 
have shown longer residence time in lungs than liposomes, 
emulsions, or polymeric nanoparticles and greater stability 
against the shear forces created during the nebulization that 
may be due to their lipophilic character and small particle 
size. This make NLCs suitable for loading drugs against the 
pulmonary disorders (81). Furthermore, providing sustained 
drug release and prolonged residence time for the entrapped 
lipophilic drugs represent NLCs as promising nanocarriers for 
ocular drug delivery (82). Using NLCs, it may also be possible 
to increase the stability and bioavailability of drugs against the 
cardiovascular disorders and prolong their circulation time that 
may result in the improved treatment outcome (83). 
APPLICATION OF MODELING APPROACHES: THE NECESSITY 
OF NANOMEDICINE
Despite the innovative techniques in nanotechnology which 
may be applied for development of stable nanoparticulate sys-
tems capable of high loading capacity and targeted delivery 
of theranostics, data reliability, personalized theranostics, or 
occurrence of the unexpected phenomena appear as challeng-
ing issues (84). Modeling and simulation techniques may be 
applied in order to design safer nanoparticles with appropriate 
bioactivity and selectivity (85). Multi-scale modeling tech-
assess their functional characteristics in vivo. It may also be 
possible to evaluate the effects of surface properties, shape, 
or cellular uptake and predict nanoparticle behavior in the 
biological systems (86). Moreover, the cause(s) of failure 
in targeted drug delivery may be analyzed leading to the 
-
eling of the adhesion kinetics, transportation, and cellular 
sequestration and increase their bioavailability (88). Fur-
thermore, using the suitable algorithms enables to calculate 
than the smallest single-walled carbon nanotubes, may be 
applied for transferring proteins, genes, or ions into the 
cells. Application of the computational quantum chemistry 
enables to develop stable structures with highly-symmetrical 
geometry (90). For mimicking tumor microenvironment, 
nanoparticles may be incubated in co-culture systems that 
may facilitate designing the effective drug delivery systems. 
cellular uptake of nanoparticles or determining the co-culture 
ratios in the heterogeneous populations of cells might be of 
21
Biomed Rev 29, 2018
Nanoparticles reshape the biomedical industry
models may provide opportunities for personalized treatment 
resistance, adverse effects, or treatment response as well as 
pharmacogenomic analysis may be possible using the suitable 
modeling techniques (93). For personalized nanoparticle drug 
delivery into the blood vessels, isogeometric analysis may be 
applied for simulating the vascular permeability, binding, and 
transport of nanoparticles. Appropriate modeling approaches 
enable to assess the hydrodynamic conditions, vascular 
geometry, or surface density of the endothelial receptors 
(94). Besides providing a deeper knowledge about the patho-
mechanism of CNS diseases, modeling approaches enable 
tracking the real-time dynamics of receptors, evaluation of 
the information processing, signaling cascades, dynamics of 
synaptic connectivity, and performance of nano-engineered 
devices or multifunctional nanoparticles capable of neuronal 
stimulation (95, 96 ). Modeling methods may also be of key 
importance for designing the nanobiosensors or nanorobots 
-
plications (97-100). It appears that modeling approaches 
along with nanointerventions would dramatically affect the 
health-care system.
CONCLUSION 
Selective drug delivery to the target tissues or organs which 
results in the improved bioavailability and reduced side 
effects of therapeutics, has been a challenging issue. Nano-
technology, an attractive interdisciplinary topic by which 
a wide variety of highly-advanced devices or biomaterials 
may be developed for early disease diagnosis or targeted 
therapy, has opened up a novel frontier in biomedicine. 
Nanotech-based research efforts have provided remarkable 
of overcoming the biological barriers and providing improved 
treatment outcomes. Using nanotechnology tools enables 
to obtain deeper knowledge about the pathomechanisms of 
a variety of disorders leading to the development of more 
effective therapeutics. Designing the nanopharmaceuticals 
with minimal toxicity and improved bioavailability as well 
as the biomaterials capable of interaction with biological 
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